These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3146749)

  • 1. UVB-induced melanocyte proliferation and 5-S-cysteinyldopa excretion in dysplastic nevus syndrome.
    Stierner U; Augustsson A; Rosdahl I; Kågedal B; Suurküla M
    Photodermatol; 1988 Oct; 5(5):218-23. PubMed ID: 3146749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanocytes, moles and melanoma--a study on UV effects.
    Stierner U
    Acta Derm Venereol Suppl (Stockh); 1991; 168():1-31. PubMed ID: 1814138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary excretion of 5-S-cysteinyldopa in relation to skin type, UVB-induced erythema, and melanocyte proliferation in human skin.
    Stierner U; Rosdahl I; Augustsson A; Kågedal B
    J Invest Dermatol; 1988 Nov; 91(5):506-10. PubMed ID: 3139773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of 5-S-cysteinyldopa by high performance liquid chromatography in biopsies from patients with dysplastic melanocytic nevi.
    Halldin MM; Cook WS; Kawashima T; Crutcher WA; Fukuyama K
    Cancer Res; 1987 Jan; 47(2):636-8. PubMed ID: 3098416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-S-Cysteinyldopa and dopa in serum during treatment with 8-methoxypsoralen and UVA light.
    Hansson C; Rorsman H; Rosengren E; Tegner E
    Acta Derm Venereol; 1981; 61(3):251-5. PubMed ID: 6167110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM; Miller S; Gunder M
    Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-S-cysteinyldopa excretion after treatment with 8-methoxypsoralen and UVA light.
    Agrup G; Hansson C; Rorsman H; Rosengren A-M ; Rosengren E; Tegner E
    J Invest Dermatol; 1978 Jan; 70(1):25-6. PubMed ID: 618976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocyte mitosis in UVB-irradiated mouse skin.
    Rosdahl IK
    Acta Derm Venereol; 1978; 58(3):217-21. PubMed ID: 78635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The recognition of UV-irradiation melanocyte with HMB-45 monoclonal antibody.
    Cheng H; Sun GJ; Thiele B; Wolff HH
    Chin Med J (Engl); 1994 Mar; 107(3):225-9. PubMed ID: 8088186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
    Sameshima T; Morishima T
    Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary excretion of 5-S-cysteinyldopa is enhanced by PUVA and is independent of skin type.
    Tardy J; Barrois JP; Bendelac A; Leonard F; Triller R; Jardillier JC; Kalis B
    Photodermatol; 1987 Aug; 4(4):205-8. PubMed ID: 3124084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
    Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy.
    Kikuchi K; Wakamatsu K; Tada Y; Komine M; Ito S; Tamaki K
    Clin Exp Dermatol; 2008 Nov; 33(6):750-3. PubMed ID: 18954414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-S-cysteinyldopa and pigment response to UVA light.
    Tegner E; Rorsman H; Rosengren E
    Acta Derm Venereol; 1983; 63(1):21-5. PubMed ID: 6191484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local and systemic effects on the epidermal melanocyte population in UV-irradiated mouse skin.
    Rosdahl IK
    J Invest Dermatol; 1979 Oct; 73(4):306-9. PubMed ID: 479635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
    Marnot D; Decaux F; Berthelot P; Kalis B; Jardillier JC; Warren L
    Cancer Detect Prev; 1983; 6(1-2):303-10. PubMed ID: 6411338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comet assay demonstrates a higher ultraviolet B sensitivity to DNA damage in dysplastic nevus cells than in common melanocytic nevus cells and foreskin melanocytes.
    Noz KC; Bauwens M; van Buul PP; Vrolijk H; Schothorst AA; Pavel S; Tanke HJ; Vermeer BJ
    J Invest Dermatol; 1996 Jun; 106(6):1198-202. PubMed ID: 8752657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
    Paul E; Graef V; Ruppel R
    Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.